Qubiotech Information

Qubio builds AI software that transforms neuroimaging into objective, quantified biomarkers — giving clinicians a reliable second opinion on some of the most complex diseases to diagnose. Our platform, Neurocloud, automates the analysis of PET, MRI and SPECT studies, delivering a full quantitative report in minutes. No subjectivity. No inter-observer variability. Just reproducible data that neurologists, radiologists and nuclear medicine physicians can act on with confidence. What we analyse: - PET — amyloid quantification in Centiloid scale, FDG metabolism and dopaminergic studies - MRI — brain atrophy, white matter lesions and longitudinal follow-up (Multiple Sclerosis, dementia) - SPECT — perfusion and dopaminergic studies (Parkinsonisms) - SISCOM — ictal/interictal subtraction for refractory epilepsy surgical planning Where we are: - 40+ hospitals across Spain, Portugal, Italy and Brazil - Integrated in platforms including Claritas - CE marked | ANVISA Brazil | FDA clearance in progress - Spin-off of the University Hospital of Santiago de Compostela (CHUS) Beyond clinical practice: We collaborate with pharma companies on research, clinical studies and commercial partnerships — always with one focus: better outcomes for patients. Neurocloud integrates invisibly into existing clinical workflows — compatible with PACS, deployable on cloud, on-premise or hybrid — with full data privacy compliance. We started with a clear goal: bring the precision of quantitative neuroimaging to real clinical practice, at a cost that makes it accessible. Augmented Neuroimaging. That's Qubio.